Robert Atchinson

CIK 1403404 · last filed 2024-05-08

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

13

Total Filings

30

Lifetime Open-Market Net

-$249.58M

Filer Profile

Reported Address
200 CLARENDON STREET
52ND FLOOR
BOSTON, MA 02116
Related Filers
ADAGE CAPITAL PARTNERS GP, L.L.C. — 128 joint filings, latest 2023-07-10
Adage Capital Partners, L.P. — 128 joint filings, latest 2023-07-10
Adage Capital Advisors, L.L.C. — 127 joint filings, latest 2023-05-10
GCM Grosvenor Inc. — 8 joint filings, latest 2023-05-10
Adage Capital Management, L.P. — 7 joint filings, latest 2025-10-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ABEO 10%+ Owner $6.00 $0 1 2024-05-08
GCM Grosvenor Inc. (GCMGW) Delisted 10%+ Owner 4,318,049 $0.01 $41.0K -$18.22M 2 2023-05-10
Vitae Pharmaceuticals, Inc (VTAE) Delisted 10%+ Owner 2,375,000 -$106.86M 1 2016-09-16
FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted 10%+ Owner 2,539,949 $38.00 $96.52M -$17.34M 1 2015-10-19
Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted 10%+ Owner 5,639,366 $47.50M 1 2015-05-04
AMAG PHARMACEUTICALS, INC. (AMAG) Delisted 10%+ Owner 2,706,592 -$167.61M 9 2015-01-09
Calithera Biosciences, Inc. (CALA) Delisted 10%+ Owner 129,184 $0.00 $39 $40.00M 1 2014-10-03
HeartWare International, Inc. (HTWR) Delisted 10%+ Owner 1,996,889 $38.47M 1 2014-09-16
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted 10%+ Owner 510,147 $8.37 $4.27M $0 1 2014-02-20
BOULDER BRANDS, INC. (BDBD) Delisted 10%+ Owner 6,497,978 -$14.93M 1 2013-01-25
Sleep Number Corp (SCSS) Delisted 10%+ Owner 5,415,000 -$5.45M 2 2011-02-11
Cardiome Pharma Corp (CRME) Delisted 10%+ Owner 6,700,000 -$45.14M 2 2010-04-16
BOULDER BRANDS, INC. (SMBL) Delisted 10%+ Owner 4,480,724 $0 1 2007-12-14

Recent Filings · Page 2 of 3

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2014-02-20 CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Conv (C) +2,477,875 $0 EDGAR
2013-09-03 AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Disp (D) −193,000 -$4.67M EDGAR
2013-08-28 AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Disp (D) −75,500 -$1.89M EDGAR
2013-08-02 AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Disp (D) −900,190 -$20.81M EDGAR
2013-01-25 BOULDER BRANDS, INC. (BDBD) Delisted Sell (S) −1,103,415 -$14.93M EDGAR
2012-07-27 Buy (P) +3,020,000 $37.37M
2012-07-18 Buy (P) +765,000 $8.58M
2012-04-26 Buy (P) +500,000 $7.00M
2012-04-26 Buy (P) +1,000,000 $13.97M
2012-03-05 AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Buy (P) +1,821,935 $28.33M EDGAR
Showing 1120 of 30
Page 2 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.